| Business Summary | | ISTA
Pharmaceuticals
discovers,
develops
and
markets
new
remedies
for
diseases
and
conditions
of
the
eye.
Its
product
development
efforts
are
focused
on
using
highly
purified
formulations
of
the
hyaluronidase
enzyme
to
treat
diseases
and
conditions
such
as
vitreous
hemorrhage,
diabetic
retinopathy,
corneal
opacification
and
keratoconus.
Each
of
these
conditions
affects
a
significant
number
of
patients
worldwide
and
can
impair
vision
and
potentially
cause
blindness.
ISTA's
lead
product
candidate,
Vitrase,
a
proprietary
formulation
of
hyaluronidase,
is
designed
for
the
treatment
of
severe
vitreous
hemorrhage
and
diabetic
retinopathy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ISTA
Pharmaceuticals
discovers
and
develops
new
remedies
for
diseases
and
conditions
of
the
eye,
including
vitreous
hemorrhage,
diabetic
retinopathy,
corneal
opacification
and
keratoconus.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
applicable
to
Common
decreased
66%
to
$10.1
million.
Lower
loss
reflects
higher
net
interest
income
and
the
absence
of
$19.2
million
of
deemed
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Robert McNeil, Ph.D., 57 Chairman | -- | Edward Danse, 48 Pres,
CEO, Director | $291K | J. MacRae, 48 Exec.
VP, COO, Chief Financial Officer | 239K | Hampar Karageozian, 61 Sr.
VP, Discovery and CTO | 250K | David Waltz, 49 VP-Fin. | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|